Cybin Inc., a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 3-5, 2025. The session will be webcast live on Friday, September 5, at 10:20 a.m. ET, with an archived replay available on Cybin's investor relations website at https://ibn.fm/N8ObB.
The company's participation in this major healthcare conference underscores the growing importance of innovative mental health treatments and the significant unmet needs in neuropsychiatry. Cybin is developing next-generation treatment options for mental healthcare, focusing on novel compounds that could revolutionize how mental health conditions are treated. The company's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder.
CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address serious conditions where current treatments are inadequate. This designation accelerates the development and review process for drugs that may demonstrate substantial improvement over available therapies. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, with additional research pipeline compounds focused on 5-HT receptors.
The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. Cybin's operational presence spans Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to addressing mental health challenges. The company's commitment to developing effective and durable treatment options comes at a critical time when mental health disorders affect millions worldwide, creating substantial economic and social burdens.
BioMedWire, the specialized communications platform that distributed this announcement, focuses on developments in biotechnology, biomedical sciences, and life sciences sectors. The platform is part of the Dynamic Brand Portfolio that provides comprehensive corporate communications solutions, including wire distribution, article syndication, and social media outreach. For more information about BioMedWire's services, visit https://www.BioMedWire.com.
